Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Immunome (IMNM) has issued an update.
Bob Lapetina is set to depart from his executive roles at Immunome, Inc. on May 10, 2024, to explore new opportunities, leaving behind no company disputes. Following his exit, Max Rosett will step up as the new principal accounting officer. Bringing a diverse background, including a tenure at Morphimmune, Inc. and experience at Google and the Boston Consulting Group, Rosett’s appointment consolidates his financial leadership within Immunome, underlined by his recent role as Interim CFO and EVP of Operations. This strategic shift in the financial department signals continuous evolution in the company’s executive suite.
Learn more about IMNM stock on TipRanks’ Stock Analysis page.
